NSCLC Harboring NRG1 Fusion

Oncology

9 drugs in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
Enzalutamide	Merus N.V. (MRUS)
Fludrocortisone acetate	Merus N.V. (MRUS)
New Formulation of Niraparib and Abiraterone Acetate	Merus N.V. (MRUS)

Phase 2(5)

Drug	Company
Abiraterone acetate tablets	Merus N.V. (MRUS)
Afatinib Oral Tablet	Merus N.V. (MRUS)
Enzalutamide Pill	Merus N.V. (MRUS)
MCLA-128	Merus N.V. (MRUS)
Olaparib Pill	Merus N.V. (MRUS)

N/A(1)

Drug	Company
Nano-crystalline megestrol acetate	Merus N.V. (MRUS)

BioSniper tracks 9 drugs in development for NSCLC Harboring NRG1 Fusion across 1 company.

There are 1 clinical trial targeting NSCLC Harboring NRG1 Fusion tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.